These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
524 related articles for article (PubMed ID: 27592341)
1. Evaluation of anticoagulation selection for acute venous thromboembolism. Badreldin H; Nichols H; Rimsans J; Carter D J Thromb Thrombolysis; 2017 Jan; 43(1):74-78. PubMed ID: 27592341 [TBL] [Abstract][Full Text] [Related]
2. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study. Badreldin H J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281 [TBL] [Abstract][Full Text] [Related]
4. Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. Basto AN; Fewel NP; Vo K; Stock EM; Ta M J Thromb Thrombolysis; 2018 Jan; 45(1):51-55. PubMed ID: 29086244 [TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location. Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335 [TBL] [Abstract][Full Text] [Related]
6. National Trends in Ambulatory Oral Anticoagulant Use. Barnes GD; Lucas E; Alexander GC; Goldberger ZD Am J Med; 2015 Dec; 128(12):1300-5.e2. PubMed ID: 26144101 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. Coons JC; Albert L; Bejjani A; Iasella CJ Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126 [TBL] [Abstract][Full Text] [Related]
9. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Imberti D; Pomero F; Benedetti R; Fenoglio L Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399 [TBL] [Abstract][Full Text] [Related]
10. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism. Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990 [TBL] [Abstract][Full Text] [Related]
11. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Bauersachs R; Agnelli G; Gitt AK; Monreal M; Mismetti P; Willich SN; Laeis P; Fronk EM; Bramlage P; Cohen AT; Thromb Res; 2017 Sep; 157():181-188. PubMed ID: 28780343 [TBL] [Abstract][Full Text] [Related]
12. All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism. Roetker NS; Lutsey PL; Zakai NA; Alonso A; Adam TJ; MacLehose RF Thromb Haemost; 2018 Sep; 118(9):1637-1645. PubMed ID: 30103250 [TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Perales IJ; San Agustin K; DeAngelo J; Campbell AM Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028 [No Abstract] [Full Text] [Related]
14. Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols. Draper E; Parkhurst B; Carley B; Krueger K; Larson T; Griesbach S Am J Cardiovasc Drugs; 2017 Dec; 17(6):475-479. PubMed ID: 28887621 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population. Hedvat J; Howlett C; McCloskey J; Patel R J Thromb Thrombolysis; 2018 Nov; 46(4):483-487. PubMed ID: 30191357 [TBL] [Abstract][Full Text] [Related]
16. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Finks SW; Trujillo TC; Dobesh PP Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821 [TBL] [Abstract][Full Text] [Related]
17. Equivalent thrombotic risk with Warfarin, Dabigatran, or Enoxaparin after failure of initial direct oral anticoagulation (DOAC) therapy. Shyu M; Liu A; Srikureja A; Gregorian A; Srisuwananukorn A; Tremblay D; Naymagon L J Thromb Thrombolysis; 2024 Jun; 57(5):871-876. PubMed ID: 38643437 [TBL] [Abstract][Full Text] [Related]
18. Direct oral anticoagulants in real clinical practice: analysis of patient characteristics and prescribing patterns in a large teaching hospital. Kováčová B; Červeňová J Pharmazie; 2017 Sep; 72(9):555-560. PubMed ID: 29441984 [TBL] [Abstract][Full Text] [Related]
19. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203 [TBL] [Abstract][Full Text] [Related]
20. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]